(Date:8/28/2008)...e based in the Northeast region with more hires,pl...HARRISBURG, Pa., Aug. 28 /PRNewswire-USNewswire/ -...red a Patient Safety Liaison for the,Northeast reg...he,Pennsylvania Patient Safety Reporting System (P...tizens., "Last year in focus groups with Pennsylv...
(Date:8/28/2008)... Leading dermatology company serves growing pro... Palo Alto, CA (PRWEB) August 28,... capital firm, today announced that together with ... is leading a Series A round of financing for Prof...ntly invested $15.5 million in the round. Profex, ...
(Date:8/28/2008)...jury, not injury itself, associated with increased... News) -- A group of researchers has described hou...ght to play a key role in Alzheimer,s disease. ,...beta, was directly linked to brain cell communicat...brain cell communication increased, so did amyloid...
(Date:8/28/2008)... The Accreditation Council for Continuing Medic...ision of the College of American Pathologists (CAP... a provider of continuing medical education for ph...L (PRWEB) August 28, 2008 -- The Accreditation Cou...awarded the Education Division of the www.cap.org...
Breaking Medicine News(10 mins):Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2Health News:College of American Pathologists' Education Division Receives Top Honor 2Health News:College of American Pathologists' Education Division Receives Top Honor 3(Date:8/28/2008)...rents to protect their 11- and 12-year-olds from,m...es cervical cancer, ATLANTA, Aug 28 /PRNewswire-U...Prevention,s (CDC) National Center for Immunizatio...w public service announcements,(PSAs) targeting th...ast,organizations. The television and radio spots,...
(Date:8/28/2008)...swire-FirstCall/ --, - Results Further Support th... Under Development to Improve the Survival of Pati...), Algeta ASA (OSE: ALGETA), the Norwegian cancer...imary objective of its BC1-03 Phase II pain,pallia...gle doses of,Alpharadin in patients with painful b...
(Date:8/27/2008)...m Makes Crucial Breakthrough in Battle to Prevent ... CHICAGO, Aug. 27 /- The British Mid... scientists at The University of Nottingham,have m...r prevent the onset,of a very common type of demen...e genetically produced the first ever mouse model,...
(Date:8/26/2008)...- The Oregon Tourism Commission,launc...ice Training Program,(Q Care) this week on http:/...ng program created to support the tourism and,hosp...on. By emphasizing,the importance of quality custo...h tools and resources to better serve Oregon,s vis...
Breaking Medicine Technology:Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 2Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 4The University of Nottingham in the British Midlands Announces Breakthrough in Parkinson's Disease Research 2Oregon Tourism Commission Unveils New Online Customer Service Training Program 2Long Term Care Insurance Leader Offers Advice on Preventing Dementia the Leading Cause of Care Claims 9944 1Long Term Care Insurance Leader Offers Advice on Preventing Dementia the Leading Cause of Care Claims 9944 2Divine Corporations Personal Lubricants Shown to Block Cancer causing Viruses in a Study by the National Cancer Institute 1246 1Divine Corporations Personal Lubricants Shown to Block Cancer causing Viruses in a Study by the National Cancer Institute 1246 2LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 1LOGICARE Selects M2SYS Biometric Fingerprint Software to Ensure Patient Privacy and Protect Confidential Information 1988 2Ohio Prematurity Caucus Forming to Meet Challenge 9938 1Ohio Prematurity Caucus Forming to Meet Challenge 9938 2Ohio Prematurity Caucus Forming to Meet Challenge 9938 3..., 2007 /PRNewswire/ -- Asenapine -- an,investigati...althcare business unit of Akzo Nobel, for bipolar ...o be more effective than placebo,in treating acute...I disorder, according to new Phase III results, fr...ssociation,s 2007 Annual,Meeting. , In the three-w...
...t 2007 APA Meeting -, COLLEGEVILLE, Pa., May 21, 2...tudies examining safety and efficacy of,desvenlafa...e,inhibitor (SNRI) being studied as a potential tr...(MDD), were presented today at the,2007 American P...,Calif., by Wyeth Pharmaceuticals, a division of ...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8Avant E-Z Rack Premium Low Binding 10 l Microreach Pipet Tips are accurate, contamination free, and allow quantitative transfer of your samples without relying on silicone.
1000 L, Racked, 96 tips/rack, clear Recommended for 500 and 1000 L pipettes.
300 L, Racked, 96 tips/rack Recommended for 250 and 300 L pipettes. Can also be used with 20, 25, 50, 100 and 200 L pipette
Application: Pipette tips in a rack for single- and multichannel systems. Product features of Autoclavable Racks: Can be steam sterilized at 121 C, Tips supplied in racks with an 8 x 12 row format,
Medicine Products: